Expressing the sense of the House of Representatives regarding the Centers for Medicare & Medicaid Services developing a mobility metric to guide providers in preventing mobility loss among hospitalized older adults.

Regulatory and reimbursement policy issues relating to healthcare programs, including diabetes and diabetic retinopathy, Medicare and Medicaid, safe mobility issues, drug pricing, medical device, innovation, telemedicine/ telehealth, supply chain, and provider issues. Monitor issues regarding COVID short and long term challenges, the Public Health Emergency (PHE), pandemic issues and provider relief funding, medical technology and device innovation, supply chain issues, Medicare and Medicaid coverage and reimbursement, artificial intelligence, health care reform, rural health, telehealth, telemedicine, remote patient monitoring, quality measurement and outcomes, diabetes (including diabetic retinopathy), cardiac care, safe mobility standards, safe patient handling, and health infrastructure funding and initiatives. Hospital at Home. Health provisions of the Consolidated Appropriations Act, 2023 (Omnibus) (P.L. No: 117-328) including the Food and Drug Omnibus Reform Act (FDORA) and PREVENT Pandemics Act, and Labor-HHS Appropriations for FY23. H.R. 6833, Making continuing appropriations for fiscal year 2023, and for other purposes (P.L. No: 117-180). H.R. 4346, the CHIPS and Science Act of 2022 (P.L. No: 117-167). Safe mobility issues, including H.Res.1177, Expressing the Sense of the House of Representatives regarding the Centers for Medicare & Medicaid Services developing a mobility metric to guide providers in preventing mobility loss among hospitalized older adults.

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues relating to drug pricing, home dialysis expansion, ESRD reimbursement for Hemodialysis, 340B Drug pricing, device sterilization, MDUFA reauthorization. Issues relating to safe mobility and issues relating to diabetic retinopathy. H.R.7053/S.3792, the Hospital Inpatient Services Modernization Act and H.Res.1177.

Client expense: $470,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Expanded Telehealth Access Act (H.R.2168) Improving Access to Medicare Coverage Act of 2021 (H.R.3650/S.2048) Creating Opportunities Now and Effective Care Technologies (CONNECT) for Health Act of 2021 (S.1512/H.R.2903) Stabilizing Medicare Access to Rehabilitation and Therapy (SMART) Act of 2021 (H.R.5536) Telehealth Extension Act (H.R.6202) Protecting Medicare and American Farmers from Sequester Cuts Act (S.610) Improving Seniors' Timely Access to Care Act (H.R.3173/S.3018) Saving Access to Laboratory Services Act (H.R.8188/S.4449) Advancing Telehealth Beyond COVID-19 Act of 2021 (H.R.4040) Supporting Medicare Providers Act of 2022 (H.R.8800) H.Res 1177 - Expressing the sense of the House of Representatives regarding the Centers for Medicare & Medicaid Services developing a mobility metric to guide providers in preventing mobility loss among hospitalized older adults.

Client expense: $39,516 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

Expanded Telehealth Access Act (H.R.2168) Improving Access to Medicare Coverage Act of 2021 (H.R.3650/S.2048) Creating Opportunities Now and Effective Care Technologies (CONNECT) for Health Act of 2021 (S.1512/H.R.2903) Stabilizing Medicare Access to Rehabilitation and Therapy (SMART) Act of 2021 (H.R.5536) Telehealth Extension Act (H.R.6202) Protecting Medicare and American Farmers from Sequester Cuts Act (S.610) Improving Seniors' Timely Access to Care Act (H.R.3173/S.3018) Saving Access to Laboratory Services Act (H.R.8188/S.4449) Advancing Telehealth Beyond COVID-19 Act of 2021 (H.R.4040) Supporting Medicare Providers Act of 2022 (H.R.8800) H.Res 1177 - Expressing the sense of the House of Representatives regarding the Centers for Medicare & Medicaid Services developing a mobility metric to guide providers in preventing mobility loss among hospitalized older adults.

Client expense: $39,516 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

Regulatory and reimbursement policy issues relating to healthcare programs, including diabetes and diabetic retinopathy, Medicare and Medicaid, safe mobility issues, drug pricing, medical device, innovation, telemedicine/ telehealth, supply chain, and provider issues. Monitor issues regarding COVID short and long term challenges; the Public Health Emergency (PHE); pandemic issues and provider relief funding; medical technology and device innovation; supply chain issues; Medicare and Medicaid coverage and reimbursement; artificial intelligence; health care reform; rural health; telehealth; telemedicine; remote patient monitoring; quality measurement and outcomes; diabetes (including diabetic retinopathy); cardiac care; safe mobility standards; safe patient handling; and health infrastructure funding and initiatives. Hospital at Home. H.R. 4502/S.3062 Labor-HHS FY2022 Appropriations; H.R. 2471 FY2022 Omnibus Appropriation; S. 748, the Medicare Sequester Relief Act; H.R. 315, the Medicare Sequester COVID Moratorium Act; H.R. 5376 The Inflation Reduction Act of 2022 (P.L. No: 117-169); H.R. 8295 Labor-HHS FY2023 Appropriations; H.R. 6833 Making continuing appropriations for fiscal year 2023, and for other purposes (P.L. No: 117-180); H.R. 4346 The CHIPS and Science Act of 2022 (P.L. No: 117-167). Medical Device User Fee Amendments Reauthorization, included in P.L. No: 117-180. Safe mobility issues, including H.Res.1177, Expressing the sense of the House of Representatives regarding the Centers for Medicare & Medicaid Services developing a mobility metric to guide providers in preventing mobility loss among hospitalized older adults.

Client expense: Not reported · Firm income: $60,000

H.R. 2471 FY2022 Omnibus Appropriations; H.R. 4502/S.3062 Labor-HHS FY2022 Appropriations; H.R.8295 Labor-HHS FY2023 Appropriations; H.R. 6833 Making continuing appropriations for fiscal year 2023, and for other purposes (P.L. No: 117-180); H.R. 4346 The CHIPS and Science Act of 2022 (P.L. No: 117-167). Regulatory and reimbursement policy issues relating to healthcare programs, including diabetes and diabetic retinopathy, and Medicare and Medicaid. Monitor drug pricing, medical device, innovation, telemedicine/telehealth, supply chain, and provider issues. Medical Device User Fee Amendments Reauthorization, included in P.L. No: 117-180. Safe mobility issues, including H.Res.1177, Expressing the sense of the House of Representatives regarding the Centers for Medicare & Medicaid Services developing a mobility metric to guide providers in preventing mobility loss among hospitalized older adults.

Client expense: Not reported · Firm income: $60,000

Regulatory and reimbursement policy issues relating to healthcare programs, including Medicare and Medicaid coverage and reimbursement, safe mobility issues, diabetes and diabetic retinopathy, monitor medical device, drug pricing, supply chain, innovation, and provider issues. Monitor issues regarding COVID short and long term challenges; the Public Health Emergency (PHE); pandemic issues and provider relief funding; medical technology and device innovation; supply chain issues; Medicare and Medicaid coverage and reimbursement; artificial intelligence; health care reform; rural health; telehealth; telemedicine; remote patient monitoring; quality measurement and outcomes; cardiac care; and health infrastructure funding and initiatives. Hospital at Home. S. 748, the Medicare Sequester Relief Act; H.R. 315, the Medicare Sequester COVID Moratorium Act; H.R. 1319, the American Rescue Plan Act (P.L. 117-2); H.R. 1330, the Patient Access to Higher Quality Care Act; H.R. 5376 the Inflation Reduction Act of 2022 (P.L. No: 117-169); H.R. 8295 Labor-HHS FY2023 Appropriations; H.R. 6833 Making continuing appropriations for fiscal year 2023, and for other purposes (P.L. No: 117-180); H.R. 4346 The CHIPS and Science Act of 2022 (P.L. No: 117-167). Medical Device User Fee Amendments Reauthorization, included in P.L. No: 117-180. Safe mobility issues, including H.Res.1177, Expressing the sense of the House of Representatives regarding the Centers for Medicare & Medicaid Services developing a mobility metric to guide providers in preventing mobility loss among hospitalized older adults.

Client expense: Not reported · Firm income: $60,000

Regulatory and reimbursement policy issues impacting medical device and technology manufacturers related to federal healthcare programs, including Medicare and Medicaid, and issues related to safe patient mobility, including H.Res. 1177.

Client expense: Not reported · Firm income: $50,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues relating to drug pricing, home dialysis expansion, ESRD reimbursement for Hemodialysis, 340B Drug pricing, device sterilization, MDUFA reauthorization. Issues relating to safe mobility and issues relating to diabetic retinopathy. H.R.7053/S.3792, the Hospital Inpatient Services Modernization Act and H.Res.1177.

Client expense: $560,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to ESRD / PPS transitional technology add-on payment adjustment for new and innovative equipment and supplies. Issues regarding dialysis in the home. Issues related to S. 2025 / H.R. 5331, Patient Access to ESRD New Innovative Devices Act. Monitored drug pricing issues related to H.R. 5376 (P.L. 117-169), the Inflation Reduction Act. Issues related to safe mobility, including H.Res. 1177. Monitored H.R. 7053/S. 3792, The Hospital Inpatient Services Modernization Act and issues related to extension of the acute hospital care at home program.

Client expense: Not reported · Firm income: $50,000

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

Issues relating to drug pricing, home dialysis expansion, ESRD reimbursement for Hemodialysis, 340B Drug pricing, device sterilization, MDUFA reauthorization. Issues relating to safe mobility and issues relating to diabetic retinopathy. H.R.7053/S.3792, the Hospital Inpatient Services Modernization Act and H.Res.1177.

Client expense: $520,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Regulatory and reimbursement policy issues related to federal healthcare programs, including Medicare and Medicaid, and issues related to safe patient mobility, including H.Res. 1177.

Client expense: Not reported · Firm income: $50,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Regulatory and reimbursement policy issues relating to healthcare programs, including diabetes and diabetic retinopathy, Medicare and Medicaid, safe mobility issues, drug pricing, medical device, innovation, telemedicine/ telehealth, supply chain, and provider issues. Monitor issues regarding COVID short and long term challenges, the Public Health Emergency (PHE), pandemic issues and provider relief funding; medical technology and device innovation; supply chain issues; Medicare and Medicaid coverage and reimbursement; artificial intelligence, health care reform, rural health, telehealth, telemedicine, remote patient monitoring, quality measurement and outcomes, diabetes (including diabetic retinopathy), cardiac care, safe mobility standards, safe patient handling, and health infrastructure funding and initiatives. Hospital at Home. H.R. 4502/ S.3062 Labor-HHS FY 22 Appropriations, H.R. 2471 FY 2022 Omnibus Appropriation, S. 748, the Medicare Sequester Relief Act, H.R. 315, the Medicare Sequester COVID Moratorium Act, H.R. 5376 the Build Back Better Act, H.R.8295 Labor-HHS FY23 Appropriations, H.Res.1177 Expressing the sense of the House of Representatives regarding the Centers for Medicare & Medicaid Services developing a mobility metric to guide providers in preventing mobility loss among hospitalized older adults.

Client expense: Not reported · Firm income: $60,000

H.R. 2471 FY 2022 Omnibus Appropriations, H.R. 4502/ S.3062 Labor-HHS FY 22 Appropriations, H.R.8295 Labor-HHS FY23 Appropriations. Regulatory and reimbursement policy issues relating to healthcare programs, including diabetes and diabetic retinopathy, Medicare and Medicaid and safe mobility issues. Monitor drug pricing, medical device, innovation, telemedicine/ telehealth, supply chain, and provider issues, H.Res.1177 Expressing the sense of the House of Representatives regarding the Centers for Medicare & Medicaid Services developing a mobility metric to guide providers in preventing mobility loss among hospitalized older adults.

Client expense: Not reported · Firm income: $60,000

Regulatory and reimbursement policy issues relating to healthcare programs, including Medicare and Medicaid coverage and reimbursement, safe mobility issues, diabetes and diabetic retinopathy, monitor medical device, drug pricing, supply chain, innovation, and provider issues. Monitor issues regarding COVID short and long term challenges, the Public Health Emergency (PHE), pandemic issues and provider relief funding; medical technology and device innovation; supply chain issues; Medicare and Medicaid coverage and reimbursement; artificial intelligence, health care reform, rural health, telehealth, telemedicine, remote patient monitoring, quality measurement and outcomes, cardiac care, and health infrastructure funding and initiatives, Hospital at Home. S. 748, the Medicare Sequester Relief Act, H.R. 315, the Medicare Sequester COVID Moratorium Act, H.R. 1319, the American Rescue Plan Act, P.L. 117-2, H.R. 1330, the Patient Access to Higher Quality Care Act, H.R. 5376 the Build Back Better Act, H.R.8295 Labor-HHS FY23 Appropriations, H.Res.1177 Expressing the sense of the House of Representatives regarding the Centers for Medicare & Medicaid Services developing a mobility metric to guide providers in preventing mobility loss among hospitalized older adults.

Client expense: Not reported · Firm income: $60,000